Seema Kumari1,2, James Yun3,4, James R Soares5, Pei N Ding1,4. 1. Medical Oncology Department, Nepean Hospital Cancer Care Centre, Kingswood, New South Wales, Australia. 2. Medical Oncology Department, Westmead Hospital Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia. 3. Clinical Immunology and Allergy, Nepean Hospital, Kingswood, New South Wales, Australia. 4. The University of Sydney, Camperdown, New South Wales, Australia. 5. Intensive Care Unit, Nepean Hospital, Kingswood, New South Wales, Australia.
Abstract
BACKGROUND: Nivolumab is an anti-PD1 immune checkpoint inhibitor commonly used for the treatment of solid organ and hematological malignancies. Severe infusion reaction due to nivolumab is quite rare. CASE: We report a case of severe infusion reaction due to nivolumab necessitating ICU admission and withdrawal of further nivolumab use in a patient with metastatic non-small cell lung cancer. CONCLUSION: Our knowledge and expertise with the use of immune checkpoint inhibitors are still evolving. This report highlights one of the rare possible side-effects that clinicians and patients may have to face with increasing indications and use of nivolumab in day to day practice.
BACKGROUND:Nivolumab is an anti-PD1 immune checkpoint inhibitor commonly used for the treatment of solid organ and hematological malignancies. Severe infusion reaction due to nivolumab is quite rare. CASE: We report a case of severe infusion reaction due to nivolumab necessitating ICU admission and withdrawal of further nivolumab use in a patient with metastatic non-small cell lung cancer. CONCLUSION: Our knowledge and expertise with the use of immune checkpoint inhibitors are still evolving. This report highlights one of the rare possible side-effects that clinicians and patients may have to face with increasing indications and use of nivolumab in day to day practice.
Authors: Werner J Pichler; Jaqueline Adam; Barbara Daubner; Thomas Gentinetta; Monika Keller; Daniel Yerly Journal: Med Clin North Am Date: 2010-07 Impact factor: 5.456
Authors: Seth J Rotz; Daniel Leino; Sara Szabo; Jennifer L Mangino; Brian K Turpin; Joseph G Pressey Journal: Pediatr Blood Cancer Date: 2017-05-24 Impact factor: 3.167
Authors: Thomas K Eigentler; Jessica C Hassel; Carola Berking; Jens Aberle; Oliver Bachmann; Viktor Grünwald; Katharina C Kähler; Carmen Loquai; Niels Reinmuth; Martin Steins; Lisa Zimmer; Anna Sendl; Ralf Gutzmer Journal: Cancer Treat Rev Date: 2016-02-18 Impact factor: 12.111
Authors: Alexander Shimabukuro-Vornhagen; Philipp Gödel; Marion Subklewe; Hans Joachim Stemmler; Hans Anton Schlößer; Max Schlaak; Matthias Kochanek; Boris Böll; Michael S von Bergwelt-Baildon Journal: J Immunother Cancer Date: 2018-06-15 Impact factor: 13.751